AT-13148 is primarily investigated for its potential in cancer therapy. It functions as an inhibitor of AGC kinases, particularly targeting proteins like AKT, p70S6K, and ROCK. This makes it a promising candidate for disrupting signaling pathways that promote tumor growth and survival. Research focuses on its use in treating solid tumors, where it may enhance the effectiveness of existing treatments or overcome resistance mechanisms. Additionally, its role in inhibiting cell proliferation and inducing apoptosis is being explored for various cancer types, including breast, prostate, and ovarian cancers. Clinical studies aim to determine its safety, efficacy, and optimal dosing regimens in combination with other therapies.